[Miliary tuberculosis in a patient with morbus Bechterew treated with tumour necrosis factor-alpha]

Ugeskr Laeger. 2014 Dec 15;176(25A):V11120642.
[Article in Danish]


Tumour necrosis factor (TNF)-α inhibitors are registered for treatment of several severe dermatologic, rheumatologic and gastrointestinal diseases. Due to TNF-α's important role in the immune system patients have increased risk of serious infections during treatment with TNF-α inhibitor. We here present a case of miliary tuberculosis complicated by pericardial effusion in a Danish man treated with TNF-α inhibitor that emphasizes the need for rapid examination of new symptoms in this patient category.

Publication types

  • Case Reports

MeSH terms

  • Adalimumab / adverse effects*
  • Adalimumab / therapeutic use
  • Antirheumatic Agents / adverse effects*
  • Antirheumatic Agents / therapeutic use
  • Antitubercular Agents / therapeutic use
  • Humans
  • Male
  • Middle Aged
  • Mycobacterium tuberculosis / isolation & purification
  • Radiography
  • Spondylitis, Ankylosing / drug therapy
  • Tuberculosis, Miliary / diagnosis*
  • Tuberculosis, Miliary / diagnostic imaging
  • Tuberculosis, Miliary / drug therapy
  • Tuberculosis, Miliary / immunology*
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors*


  • Antirheumatic Agents
  • Antitubercular Agents
  • Tumor Necrosis Factor-alpha
  • Adalimumab